QR Code

Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer

Metaplastic breast cancer (MBC) is a rare and aggressive subtype of breast cancer. Tumor characteristics typically feature estrogen receptor, progesterone receptor, and HER2-negative, triple-negative breast cancer (TNBC), with a poorer prognosis relative to pure invasive ductal or lobular disease. R...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Elan Gorshein, Kant Matsuda, Gregory Riedlinger, Levi Sokol, Lorna Rodriguez-Rodriguez, Firas Eladoumikdachi, Miral Grandhi, Shridar Ganesan, Deborah L. Toppmeyer, Lindsay Potdevin, Kathleen Toomey, Kim M. Hirshfield, Nancy Chan
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Karger Publishers 2021-06-01
Rangatū:Case Reports in Oncology
Ngā marau:
metaplastic breast cancer
exceptional response
immunotherapy
program death ligand-1
Urunga tuihono:https://www.karger.com/Article/FullText/515510
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite